Civitas Therapeutics Email Format

Biotechnology Research11-50 Employees

Civitas Therapeutics is a privately-held biopharmaceutical company focused on developing a robust pipeline of inhaled therapeutics with the clinically-proven ARCUS dry powder pulmonary delivery platform.  The company’s lead program, CVT-301, is being developed as adjunctive PRN therapy to provide Parkinson’s disease patients with rapid and reliable relief from intermittent debilitating motor fluctuations (OFF episodes).  

The ARCUS platform is a proprietary dry powder and device combination with a unique ability to deliver a large, precise dose independent of inspiratory flow rate from a simple, breath actuated device and is protected by a large intellectual property estate.

✕

Access Insights for Civitas Therapeutics and Millions of Other Companies

Sign up for full access to Civitas Therapeutics information.

Continue with GoogleContinue with Microsoft

No credit card needed

OR

Work email

Create AccountBy creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Sign up for free to view info

Company overview Employee directory